Stopping vs. Continuing Riociguat After Lung Blood Vessel Treatment
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests whether patients with chronic thromboembolic pulmonary hypertension who have improved after a procedure called balloon pulmonary angioplasty can safely stop taking the drug riociguat, or whether they should continue it. The goal is to learn whether stopping the medication is safe or if staying on it prevents symptoms from returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have chronic thromboembolic pulmonary hypertension (CTEPH)—a serious lung condition—that either cannot be surgically repaired or persisted after surgery, and you must have improved significantly after balloon pulmonary angioplasty (a catheter-based procedure).
- You must have been taking riociguat alone (no other lung-pressure medications) for at least 6 months, with a stable dose for the past 3 months.
- Your most recent balloon angioplasty procedure must have been at least 6 months ago.
- You must be able to walk at least 150 meters in 6 minutes without stopping.
- You cannot take any other pulmonary hypertension medications besides riociguat (such as endothelin receptor antagonists or phosphodiesterase-5 inhibitors).
- Your liver and kidney function must be normal or near-normal, and you cannot have severe lung disease, heart failure, or a history of life-threatening coughing up of blood.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether starting specific medicines for CTEPH and then doing balloon pulmonary angioplasty (BPA) can improve how well the right side of the heart is working. It may help people who cannot have surgery (PTE) and are newly starting CTEPH/PAH-targeted treatment.
This study looks at how a minimally invasive procedure called balloon pulmonary angioplasty (BPA) helps patients with chronic blood clots in the lungs improve their heart function and overall recovery. Researchers will measure blood flow patterns in your arteries before and after the procedure to understand how well your heart recovers.
This trial is for people with a type of long-term blood clot in the lungs (CTEPH) who have been taking riociguat for at least 12 weeks. It will see what happens when the medication is stopped, focusing on how the right side of the heart is doing.
This trial tests switching from sildenafil to a newer medicine called riociguat for people with CTEPH (a type of lung blood pressure problem) who still have symptoms after a balloon procedure. The goal is to see if the switch helps them feel better.
This trial tests switching from one blood vessel relaxer (a PDE-5i) to another (riociguat) for people with pulmonary arterial hypertension who are already on three medications. It looks at how this switch affects their condition over 6 months.
This trial tests whether a procedure called balloon pulmonary angioplasty is safe and effective for people with chronic thromboembolic disease in the lungs, especially when surgery isn’t an option. If you have CTEPH, it may help improve lung blood flow and symptoms.
Hear when a new CTEPH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.